Dengue Vaccine Recommendations

Below are summaries of recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP). For the full text of the recommendations, see Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021.

Dengue vaccine is recommended for adolescents who are:

  • 9–16 years old
  • Live in areas where dengue occurs frequently or continuously including:
    • American Samoa
    • Puerto Rico
    • U.S. Virgin Islands
    • Federated States of Micronesia
    • Republic of Marshall Islands
    • Republic of Palau
  • Have laboratory-confirmed evidence of previous dengue infection including:

Contraindications and Precautions

Do not administer dengue vaccines to

  • A person who lacks laboratory evidence of previous dengue infection
  • A person who has ever had a severe allergic reaction (e.g., anaphylaxis) after a previous dose of this vaccine
  • A person who has a severe allergy to any vaccine component (see the Dengvaxia package insert)
  • A person with severe immunodeficiency or immunosuppression due to underlying disease or therapy, including persons with symptomatic HIV infection or CD4+ T-lymphocyte count of <200/mm3.
  • A person who lacks laboratory evidence of a previous dengue infection

Healthcare providers should weigh the risks of vaccination against the risk for dengue for the following populations:

  • Pregnant people
  • Breastfeeding people
  • Persons with HIV infection
  • Persons with moderate or severe acute illness with or without fever